uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 juin 2023 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
15 mai 2023 07h05 HE
|
uniQure Inc.
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an...
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
09 mai 2023 07h05 HE
|
uniQure Inc.
~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in...
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
02 mai 2023 16h40 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2023 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 mars 2023 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in March
02 mars 2023 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
27 févr. 2023 07h05 HE
|
uniQure Inc.
~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington’s disease –...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
23 févr. 2023 08h05 HE
|
uniQure Inc.
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for...
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
21 févr. 2023 07h05 HE
|
uniQure Inc.
~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the...